Human disease
hepatocellular carcinoma
Mondo defines it as: “A malignant tumor that arises from hepatocytes. Hepatocellular carcinoma is relatively rare in the United States but very common in all African countries south of the Sahara and in Southeast Asia. Most cases are seen in patients over the age of 50 years, but this tumor can also occur in younger individuals and even in children. Hepatocellular carcinoma is more common in males than females and is associated with hepatitis B, hepatitis C, chronic alcohol abuse and cirrhosis. Serum elevation of alpha-fetoprotein occurs in a large percentage of patients with hepatocellular carcinoma. Grossly, hepatocellular carcinoma may present as a single mass, as multiple nodules, or as diffuse liver involvement. Microscopically, there is a wide range of differentiation from tumor to tumor (well differentiated to poorly differentiated tumors). Hepatocellular carcinomas quickly metastasize to regional lymph nodes and lung. The overall median survival of untreated liver cell carcinoma is about 4 months. The most effective treatment of hepatocellular carcinoma is complete resection of the tumor. Lately, an increasing number of tumors have been treated with liver transplantation.”
1 disease group in OMIA reaches this disease, through OMIA's own Mondo link or its OMIM numbers. The page shows the chain. It does not say whether an animal is a model of this disease.
Animal diseases
By natural-model score for this disease, highest first. The score says how complete and how well supported each chain is, by stated rules. How the score works.
| OMIA group | Name | Found by | Species | The chain reached | Score |
|---|---|---|---|---|---|
| 1990 | Cancer, TP53-related | OMIA's OMIM numbers | 5 | Drug |
84.9
|
Human genes
Each human gene of these disease groups that Open Targets links to this disease.
| Human gene | Score | Evidence |
|---|---|---|
| TP53 | 0.80 | 6,833 |
| KRAS | 0.51 | 498 |
Drugs tested for this disease
Each ChEMBL drug that has been tested for this disease, and the human genes above it acts on, if any. Open Targets gives some drugs, such as most enzyme replacement therapies, no target gene.
| Drug | Acts on | Latest stage for this disease |
|---|---|---|
| Alcohol | None of these genes | Approved |
| Cabozantinib | None of these genes | Approved |
| Durvalumab | None of these genes | Approved |
| Fluorouracil | None of these genes | Approved |
| Leucovorin | None of these genes | Approved |
| Oxaliplatin | None of these genes | Approved |
| Sorafenib | None of these genes | Approved |
| Tremelimumab | None of these genes | Approved |
| Acetazolamide | None of these genes | Phase 3 |
| Adebrelimab | None of these genes | Phase 3 |
| Aglatimagene Besadenovec | None of these genes | Phase 3 |
| Albumin Human | None of these genes | Phase 3 |
| Arginine Hydrochloride | None of these genes | Phase 3 |
| Atezolizumab | None of these genes | Phase 3 |
| Benmelstobart | None of these genes | Phase 3 |
| Bevacizumab | None of these genes | Phase 3 |
| Brivanib | None of these genes | Phase 3 |
| Brivanib Alaninate | None of these genes | Phase 3 |
| Cadonilimab | None of these genes | Phase 3 |
| Camrelizumab | None of these genes | Phase 3 |
| Capecitabine | None of these genes | Phase 3 |
| Carboplatin | None of these genes | Phase 3 |
| Catequentinib | None of these genes | Phase 3 |
| Chlorotrianisene | None of these genes | Phase 3 |
| Cisplatin | None of these genes | Phase 3 |
| Cs-1003 | None of these genes | Phase 3 |
| Cyclophosphamide Anhydrous | None of these genes | Phase 3 |
| Daclatasvir | None of these genes | Phase 3 |
| Dasabuvir | None of these genes | Phase 3 |
| Dexamethasone | None of these genes | Phase 3 |
| Doxorubicin | None of these genes | Phase 3 |
| Doxribtimine | None of these genes | Phase 3 |
| Entecavir Anhydrous | None of these genes | Phase 3 |
| Epirubicin | None of these genes | Phase 3 |
| Erlotinib | None of these genes | Phase 3 |
| Ethiodized Oil | None of these genes | Phase 3 |
| Etoposide | None of these genes | Phase 3 |
| Everolimus | None of these genes | Phase 3 |
| Fexapotide | None of these genes | Phase 3 |
| Gemcitabine | None of these genes | Phase 3 |
| Gilvetmab | None of these genes | Phase 3 |
| Hydroxycamptothecin | None of these genes | Phase 3 |
| Icaritin | None of these genes | Phase 3 |
| Interferon Alfa-2b | None of these genes | Phase 3 |
| Iodine | None of these genes | Phase 3 |
| Ipilimumab | None of these genes | Phase 3 |
| Irinotecan | None of these genes | Phase 3 |
| Ledipasvir | None of these genes | Phase 3 |
| Lenvatinib | None of these genes | Phase 3 |
| Levamisole | None of these genes | Phase 3 |
| Levoleucovorin | None of these genes | Phase 3 |
| Linifanib | None of these genes | Phase 3 |
| Lobaplatin | None of these genes | Phase 3 |
| Megestrol Acetate | None of these genes | Phase 3 |
| Mitomycin | None of these genes | Phase 3 |
| Muparfostat | None of these genes | Phase 3 |
| Namodenoson | None of these genes | Phase 3 |
| Nivolumab | None of these genes | Phase 3 |
| Nolatrexed | None of these genes | Phase 3 |
| Octreotide | None of these genes | Phase 3 |
| Ombitasvir | None of these genes | Phase 3 |
| Orantinib | None of these genes | Phase 3 |
| Paritaprevir | None of these genes | Phase 3 |
| Pegargiminase | None of these genes | Phase 3 |
| Peginterferon Alfa-2b | None of these genes | Phase 3 |
| Pembrolizumab | None of these genes | Phase 3 |
| Penpulimab | None of these genes | Phase 3 |
| Peretinoin | None of these genes | Phase 3 |
| Pexastimogene Devacirepvec | None of these genes | Phase 3 |
| Pirarubicin | None of these genes | Phase 3 |
| Pravastatin | None of these genes | Phase 3 |
| Ramucirumab | None of these genes | Phase 3 |
| Regorafenib | None of these genes | Phase 3 |
| Ribavirin | None of these genes | Phase 3 |
| Rilvegostomig | None of these genes | Phase 3 |
| Ritonavir | None of these genes | Phase 3 |
| Rivoceranib | None of these genes | Phase 3 |
| Seocalcitol | None of these genes | Phase 3 |
| Serplulimab | None of these genes | Phase 3 |
| Simeprevir | None of these genes | Phase 3 |
| Sintilimab | None of these genes | Phase 3 |
| Siponimod | None of these genes | Phase 3 |
| Sirolimus | None of these genes | Phase 3 |
| Sitravatinib | None of these genes | Phase 3 |
| Sofosbuvir | None of these genes | Phase 3 |
| Sunitinib | None of these genes | Phase 3 |
| Talaporfin | None of these genes | Phase 3 |
| Tamoxifen | None of these genes | Phase 3 |
| Tenofovir Anhydrous | None of these genes | Phase 3 |
| Tenofovir Disoproxil | None of these genes | Phase 3 |
| Thalidomide | None of these genes | Phase 3 |
| Tiragolumab | None of these genes | Phase 3 |
| Tislelizumab | None of these genes | Phase 3 |
| Tivantinib | None of these genes | Phase 3 |
| Toripalimab | None of these genes | Phase 3 |
| Trimetazidine | None of these genes | Phase 3 |
| Vincristine | None of these genes | Phase 3 |
| Yttrium | None of these genes | Phase 3 |
| Zinc Acexamate | None of these genes | Phase 3 |
| Arsenic Trioxide | None of these genes | Phase 2/3 |
| Avelumab | None of these genes | Phase 2/3 |
| Batabulin | None of these genes | Phase 2/3 |
| Budigalimab | None of these genes | Phase 2/3 |
| Cantharides Tincture | None of these genes | Phase 2/3 |
| Finotonlimab | None of these genes | Phase 2/3 |
| Idarubicin | None of these genes | Phase 2/3 |
| Lanreotide | None of these genes | Phase 2/3 |
| Livmoniplimab | None of these genes | Phase 2/3 |
| Memantine | None of these genes | Phase 2/3 |
| Nadroparin Calcium | None of these genes | Phase 2/3 |
| Nicardipine | None of these genes | Phase 2/3 |
| Tacrolimus Anhydrous | None of these genes | Phase 2/3 |
| Tirapazamine | None of these genes | Phase 2/3 |
| 2-Mercaptoethanesulfonic Acid | None of these genes | Phase 2 |
| Abc-294640 | None of these genes | Phase 2 |
| Abemaciclib | None of these genes | Phase 2 |
| Adagloxad Simolenin | None of these genes | Phase 2 |
| Adakitug | None of these genes | Phase 2 |
| Adefovir | None of these genes | Phase 2 |
| Aldesleukin | None of these genes | Phase 2 |
| Alvocidib | None of these genes | Phase 2 |
| Amcasertib | None of these genes | Phase 2 |
| Amino Acids | None of these genes | Phase 2 |
| Amivantamab | None of these genes | Phase 2 |
| Amsilarotene | None of these genes | Phase 2 |
| Antilymphocyte Immunoglobulin (Horse) | None of these genes | Phase 2 |
| Antimony | None of these genes | Phase 2 |
| Apl-501 | None of these genes | Phase 2 |
| Ascrinvacumab | None of these genes | Phase 2 |
| Aspirin | None of these genes | Phase 2 |
| Atorvastatin | None of these genes | Phase 2 |
| Axitinib | None of these genes | Phase 2 |
| Baclofen | None of these genes | Phase 2 |
| Bavituximab | None of these genes | Phase 2 |
| Becotatug Vedotin | None of these genes | Phase 2 |
| Belzutifan | None of these genes | Phase 2 |
| Bms-813160 | None of these genes | Phase 2 |
| Bortezomib | None of these genes | Phase 2 |
| Cabiralizumab | None of these genes | Phase 2 |
| Cannabidiol | None of these genes | Phase 2 |
| Capmatinib | None of these genes | Phase 2 |
| Carotuximab | None of these genes | Phase 2 |
| Carvedilol | None of these genes | Phase 2 |
| Casdozokitug | None of these genes | Phase 2 |
| Cediranib | None of these genes | Phase 2 |
| Celecoxib | None of these genes | Phase 2 |
| Cemiplimab | None of these genes | Phase 2 |
| Ceritinib | None of these genes | Phase 2 |
| Cetuximab | None of these genes | Phase 2 |
| Cixutumumab | None of these genes | Phase 2 |
| Clemizole | None of these genes | Phase 2 |
| Cobolimab | None of these genes | Phase 2 |
| Codrituzumab | None of these genes | Phase 2 |
| Colchicine | None of these genes | Phase 2 |
| Cyclosporine | None of these genes | Phase 2 |
| Dalpiciclib | None of these genes | Phase 2 |
| Danburstotug | None of these genes | Phase 2 |
| Darinaparsin | None of these genes | Phase 2 |
| Dasatinib Anhydrous | None of these genes | Phase 2 |
| Denosumab | None of these genes | Phase 2 |
| Docetaxel Anhydrous | None of these genes | Phase 2 |
| Domvanalimab | None of these genes | Phase 2 |
| Dostarlimab | None of these genes | Phase 2 |
| Dovitinib | None of these genes | Phase 2 |
| Dronabinol | None of these genes | Phase 2 |
| Elbasvir | None of these genes | Phase 2 |
| Endostatin | None of these genes | Phase 2 |
| Endostatin, N-Terminal-Mggshhhhh | None of these genes | Phase 2 |
| Enfortumab Vedotin | None of these genes | Phase 2 |
| Envafolimab | None of these genes | Phase 2 |
| Enzalutamide | None of these genes | Phase 2 |
| Epalrestat | None of these genes | Phase 2 |
| Epinephrine | None of these genes | Phase 2 |
| Erfonrilimab | None of these genes | Phase 2 |
| Etodolac | None of these genes | Phase 2 |
| Exatecan | None of these genes | Phase 2 |
| Ezurpimtrostat | None of these genes | Phase 2 |
| Fianlimab | None of these genes | Phase 2 |
| Filgrastim | None of these genes | Phase 2 |
| Floxuridine | None of these genes | Phase 2 |
| Fludarabine | None of these genes | Phase 2 |
| Foslinanib | None of these genes | Phase 2 |
| Fostamatinib | None of these genes | Phase 2 |
| Fruquintinib | None of these genes | Phase 2 |
| Futibatinib | None of these genes | Phase 2 |
| Galunisertib | None of these genes | Phase 2 |
| Gefitinib | None of these genes | Phase 2 |
| Gimeracil | None of these genes | Phase 2 |
| Grazoprevir Anhydrous | None of these genes | Phase 2 |
| Guadecitabine | None of these genes | Phase 2 |
| Hiltonol | None of these genes | Phase 2 |
| Hydroxychloroquine | None of these genes | Phase 2 |
| Icariin | None of these genes | Phase 2 |
| Imatinib | None of these genes | Phase 2 |
| Interferon | None of these genes | Phase 2 |
| Interferon Alfa | None of these genes | Phase 2 |
| Interferon Alfa-2a | None of these genes | Phase 2 |
| Irpagratinib | None of these genes | Phase 2 |
| Ispinesib | None of these genes | Phase 2 |
| Ivarmacitinib | None of these genes | Phase 2 |
| Ivonescimab | None of these genes | Phase 2 |
| Lapatinib | None of these genes | Phase 2 |
| Lenalidomide | None of these genes | Phase 2 |
| Linsitinib | None of these genes | Phase 2 |
| Melphalan | None of these genes | Phase 2 |
| Metformin | None of these genes | Phase 2 |
| Methotrexate | None of these genes | Phase 2 |
| Milciclib | None of these genes | Phase 2 |
| Mipsagargin | None of these genes | Phase 2 |
| Mitoxantrone | None of these genes | Phase 2 |
| Mk-2206 | None of these genes | Phase 2 |
| Mycophenolate Mofetil | None of these genes | Phase 2 |
| Nabiximols | None of these genes | Phase 2 |
| Nimotuzumab | None of these genes | Phase 2 |
| Nintedanib | None of these genes | Phase 2 |
| Obi-3424 | None of these genes | Phase 2 |
| Oblimersen Sodium | None of these genes | Phase 2 |
| Ociperlimab | None of these genes | Phase 2 |
| Onatasertib | None of these genes | Phase 2 |
| Paclitaxel | None of these genes | Phase 2 |
| Paclitaxel Docosahexaenoic Acid | None of these genes | Phase 2 |
| Palbociclib | None of these genes | Phase 2 |
| Pasireotide | None of these genes | Phase 2 |
| Patupilone | None of these genes | Phase 2 |
| Pegenzileukin | None of these genes | Phase 2 |
| Peginterferon Alfa-2a | None of these genes | Phase 2 |
| Perflutren | None of these genes | Phase 2 |
| Pimurutamab | None of these genes | Phase 2 |
| Platinum | None of these genes | Phase 2 |
| Prednisone | None of these genes | Phase 2 |
| Propranolol | None of these genes | Phase 2 |
| P-Toluenesulfonamide | None of these genes | Phase 2 |
| Pucotenlimab | None of these genes | Phase 2 |
| Pyrazoloacridine | None of these genes | Phase 2 |
| Pyrotinib | None of these genes | Phase 2 |
| Quavonlimab | None of these genes | Phase 2 |
| Raltitrexed | None of these genes | Phase 2 |
| Refametinib | None of these genes | Phase 2 |
| Relatlimab | None of these genes | Phase 2 |
| Resminostat | None of these genes | Phase 2 |
| Ribociclib | None of these genes | Phase 2 |
| Rituximab | None of these genes | Phase 2 |
| Rosiglitazone | None of these genes | Phase 2 |
| S1? | None of these genes | Phase 2 |
| Selgantolimod | None of these genes | Phase 2 |
| Selumetinib | None of these genes | Phase 2 |
| Sonidegib | None of these genes | Phase 2 |
| Surufatinib | None of these genes | Phase 2 |
| Suvemcitug | None of these genes | Phase 2 |
| T-900607 | None of these genes | Phase 2 |
| Tadalafil | None of these genes | Phase 2 |
| Tasquinimod | None of these genes | Phase 2 |
| Taurursodiol | None of these genes | Phase 2 |
| Tazemetostat | None of these genes | Phase 2 |
| Tegafur | None of these genes | Phase 2 |
| Telatinib | None of these genes | Phase 2 |
| Temozolomide | None of these genes | Phase 2 |
| Temsirolimus | None of these genes | Phase 2 |
| Tepotinib | None of these genes | Phase 2 |
| Tertomotide | None of these genes | Phase 2 |
| Thymalfasin | None of these genes | Phase 2 |
| Tigatuzumab | None of these genes | Phase 2 |
| Tinengotinib | None of these genes | Phase 2 |
| Tiomolibdate Diammonium | None of these genes | Phase 2 |
| Tivozanib | None of these genes | Phase 2 |
| Tlc-388 | None of these genes | Phase 2 |
| Tomivosertib | None of these genes | Phase 2 |
| Trastuzumab | None of these genes | Phase 2 |
| Trebananib | None of these genes | Phase 2 |
| Tretazicar | None of these genes | Phase 2 |
| Troculeucel | None of these genes | Phase 2 |
| Tyrosine | None of these genes | Phase 2 |
| Vancomycin | None of these genes | Phase 2 |
| Vandetanib | None of these genes | Phase 2 |
| Veliparib | None of these genes | Phase 2 |
| Vipivotide Tetraxetan | None of these genes | Phase 2 |
| Visugromab | None of these genes | Phase 2 |
| Volrustomig | None of these genes | Phase 2 |
| Yh-001 | None of these genes | Phase 2 |
| Zabadinostat | None of these genes | Phase 2 |
| Zanzalintinib | None of these genes | Phase 2 |
| Zimberelimab | None of these genes | Phase 2 |
| Zinc Sulfate | None of these genes | Phase 2 |
| Zoledronic Acid Anhydrous | None of these genes | Phase 2 |
| Abx-196 | None of these genes | Phase 1/2 |
| Aeg-35156 | None of these genes | Phase 1/2 |
| Aldoxorubicin | None of these genes | Phase 1/2 |
| Allantoin | None of these genes | Phase 1/2 |
| Ascorbic Acid | None of these genes | Phase 1/2 |
| Avadomide | None of these genes | Phase 1/2 |
| Bafisontamab | None of these genes | Phase 1/2 |
| Belinostat | None of these genes | Phase 1/2 |
| Bumetanide | None of these genes | Phase 1/2 |
| C-188-9 | None of these genes | Phase 1/2 |
| Cv-8102 | None of these genes | Phase 1/2 |
| Cyc-065 | None of these genes | Phase 1/2 |
| Dalantercept | None of these genes | Phase 1/2 |
| Decitabine | None of these genes | Phase 1/2 |
| Denileukin Diftitox | None of these genes | Phase 1/2 |
| Dkn-01 | None of these genes | Phase 1/2 |
| E-7386 | None of these genes | Phase 1/2 |
| Eniluracil | None of these genes | Phase 1/2 |
| Enlonstobart | None of these genes | Phase 1/2 |
| Erdafitinib | None of these genes | Phase 1/2 |
| Fgf401 | None of these genes | Phase 1/2 |
| Fisogatinib | None of these genes | Phase 1/2 |
| Folinic Acid | None of these genes | Phase 1/2 |
| Fostroxacitabine Bralpamide | None of these genes | Phase 1/2 |
| Gataparsen | None of these genes | Phase 1/2 |
| Glutamine | None of these genes | Phase 1/2 |
| Golvatinib | None of these genes | Phase 1/2 |
| Hyaluronidase (Human Recombinant) | None of these genes | Phase 1/2 |
| Ibcasertib | None of these genes | Phase 1/2 |
| Ifinatamab Deruxtecan | None of these genes | Phase 1/2 |
| Imifoplatin | None of these genes | Phase 1/2 |
| Isatuximab | None of these genes | Phase 1/2 |
| Ivuxolimab | None of these genes | Phase 1/2 |
| Lancastotug | None of these genes | Phase 1/2 |
| Linrodostat | None of these genes | Phase 1/2 |
| Lucorafusp Alfa | None of these genes | Phase 1/2 |
| Mapatumumab | None of these genes | Phase 1/2 |
| Mb-07133 | None of these genes | Phase 1/2 |
| Muzastotug | None of these genes | Phase 1/2 |
| Napabucasin | None of these genes | Phase 1/2 |
| Nelitolimod | None of these genes | Phase 1/2 |
| Nogapendekin Alfa | None of these genes | Phase 1/2 |
| Oprozomib | None of these genes | Phase 1/2 |
| Oric-101 | None of these genes | Phase 1/2 |
| Pidilizumab | None of these genes | Phase 1/2 |
| Pr-104 | None of these genes | Phase 1/2 |
| Pxs-5505 | None of these genes | Phase 1/2 |
| Rocakinogene Sifuplasmid | None of these genes | Phase 1/2 |
| Sacituzumab Govitecan | None of these genes | Phase 1/2 |
| Sapanisertib | None of these genes | Phase 1/2 |
| Sargramostim | None of these genes | Phase 1/2 |
| Sirpiglenastat | None of these genes | Phase 1/2 |
| Spartalizumab | None of these genes | Phase 1/2 |
| Streptococcus Pneumoniae Polysaccharide Conjugated To Corynebacterium Diphtheriae Crm197 | None of these genes | Phase 1/2 |
| Sugemalimab | None of these genes | Phase 1/2 |
| Talimogene Laherparepvec | None of these genes | Phase 1/2 |
| Tebotelimab | None of these genes | Phase 1/2 |
| Tefinostat | None of these genes | Phase 1/2 |
| Tegavivint | None of these genes | Phase 1/2 |
| Tobemstomig | None of these genes | Phase 1/2 |
| Tocilizumab | None of these genes | Phase 1/2 |
| Tucidinostat | None of these genes | Phase 1/2 |
| Utomilumab | None of these genes | Phase 1/2 |
| Valemetostat | None of these genes | Phase 1/2 |
| Valganciclovir | None of these genes | Phase 1/2 |
| Varlitinib | None of these genes | Phase 1/2 |
| Vebreltinib | None of these genes | Phase 1/2 |
| Alectinib | None of these genes | Phase 1 |
| Alextatug | None of these genes | Phase 1 |
| .Alpha.-Pyrrolidinononanophenone | None of these genes | Phase 1 |
| Artesunate | None of these genes | Phase 1 |
| Azd-1480 | None of these genes | Phase 1 |
| Azd-8055 | None of these genes | Phase 1 |
| Biib-022 | None of these genes | Phase 1 |
| Cenisertib | None of these genes | Phase 1 |
| Charcoal, Activated | None of these genes | Phase 1 |
| Cytidine | None of these genes | Phase 1 |
| Danvatirsen | None of these genes | Phase 1 |
| Deferoxamine | None of these genes | Phase 1 |
| Denenicokin | None of these genes | Phase 1 |
| Dusigitumab | None of these genes | Phase 1 |
| Emibetuzumab | None of these genes | Phase 1 |
| Enmd-2076 | None of these genes | Phase 1 |
| Ery-974 | None of these genes | Phase 1 |
| Evofosfamide | None of these genes | Phase 1 |
| Exemestane | None of these genes | Phase 1 |
| Ezabenlimab | None of these genes | Phase 1 |
| Foretinib | None of these genes | Phase 1 |
| Ganetespib | None of these genes | Phase 1 |
| Guanosine | None of these genes | Phase 1 |
| H3b-6527 | None of these genes | Phase 1 |
| Hafnium Oxide | None of these genes | Phase 1 |
| Interferon Alfacon-1 | None of these genes | Phase 1 |
| Interleukin 15, Recombinant Non-Glycosylated | None of these genes | Phase 1 |
| Ipafricept | None of these genes | Phase 1 |
| Irx-2 | None of these genes | Phase 1 |
| Itacitinib | None of these genes | Phase 1 |
| Itraconazole | None of these genes | Phase 1 |
| Lucitanib | None of these genes | Phase 1 |
| Meclizine | None of these genes | Phase 1 |
| Metenkefalin | None of these genes | Phase 1 |
| Methionine | None of these genes | Phase 1 |
| Modafinil | None of these genes | Phase 1 |
| Nanrilkefusp Alfa | None of these genes | Phase 1 |
| Onartuzumab | None of these genes | Phase 1 |
| Ontuxizumab | None of these genes | Phase 1 |
| Palverafusp Alfa | None of these genes | Phase 1 |
| Panobinostat | None of these genes | Phase 1 |
| Pazopanib | None of these genes | Phase 1 |
| Pemetrexed | None of these genes | Phase 1 |
| Pentamidine | None of these genes | Phase 1 |
| Pimasertib | None of these genes | Phase 1 |
| Pomalidomide | None of these genes | Phase 1 |
| Porustobart | None of these genes | Phase 1 |
| Recombinant Human Interleukin-15 | None of these genes | Phase 1 |
| Retifanlimab | None of these genes | Phase 1 |
| Rigosertib | None of these genes | Phase 1 |
| Sar-439459 | None of these genes | Phase 1 |
| Selinexor | None of these genes | Phase 1 |
| Sf-1126 | None of these genes | Phase 1 |
| Sitagliptin | None of these genes | Phase 1 |
| Sumatriptan | None of these genes | Phase 1 |
| Suratadenoturev | None of these genes | Phase 1 |
| Tb-403 | None of these genes | Phase 1 |
| Telisotuzumab Adizutecan | None of these genes | Phase 1 |
| Tilarginine | None of these genes | Phase 1 |
| Tovetumab | None of these genes | Phase 1 |
| Tozinameran | None of these genes | Phase 1 |
| Trametinib | None of these genes | Phase 1 |
| Vactosertib | None of these genes | Phase 1 |
| Vanucizumab | None of these genes | Phase 1 |
| Vismodegib | None of these genes | Phase 1 |
| Vorinostat | None of these genes | Phase 1 |
| Vorolanib | None of these genes | Phase 1 |
| Zotiraciclib | None of these genes | Phase 1 |
| Ateganosine | None of these genes | Early phase 1 |
| Boceprevir | None of these genes | Early phase 1 |
| Tenofovir Alafenamide | None of these genes | Early phase 1 |
| Cytochlor | None of these genes | Investigational new drug |
| Adefovir Dipivoxil | None of these genes | Unknown |
| Ademetionine | None of these genes | Unknown |
| Avatrombopag | None of these genes | Unknown |
| Balstilimab | None of these genes | Unknown |
| Carmofur | None of these genes | Unknown |
| Cholecalciferol | None of these genes | Unknown |
| Daclizumab | None of these genes | Unknown |
| Ferumoxytol | None of these genes | Unknown |
| Hepatitis B Immune Globulin | None of these genes | Unknown |
| Lamivudine | None of these genes | Unknown |
| Lidocaine | None of these genes | Unknown |
| Mebendazole | None of these genes | Unknown |
| Novaferon | None of these genes | Unknown |
| Perifosine | None of these genes | Unknown |
| Phytonadione | None of these genes | Unknown |
| Porfimer Sodium | None of these genes | Unknown |
| Propofol | None of these genes | Unknown |
| Regramostim | None of these genes | Unknown |
| Rencofilstat | None of these genes | Unknown |
| Retlirafusp Alfa | None of these genes | Unknown |
| Ropeginterferon Alfa-2b | None of these genes | Unknown |
| Sevoflurane | None of these genes | Unknown |
| Sym-021 | None of these genes | Unknown |
| Telbivudine | None of these genes | Unknown |
| Ulinastatin | None of these genes | Unknown |
| Velpatasvir | None of these genes | Unknown |
| Voxilaprevir | None of these genes | Unknown |
The drug data is ChEMBL's, under CC BY-SA 3.0, and came through Open Targets release 26.09.